Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of LY2409021 versus Sitagliptin and Placebo in Type 2 Diabetes Mellitus
2013-004275-12Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adomeglivant in type 2 diabetes mellitus (T2DM) and steatosis (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in hepatic fat fraction from baseline to 6 months. Started Mar 2014; status: terminated.
02
Drugs
adomeglivant
03
Conditions
type 2 diabetes mellitus (T2DM)steatosis
Beyond the preview
Go deeper on 2013-004275-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004275-12.